Crestwood Advisors Group LLC Has $383,000 Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Crestwood Advisors Group LLC decreased its stake in AstraZeneca PLC (NASDAQ:AZN) by 17.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,916 shares of the company’s stock after selling 1,043 shares during the period. Crestwood Advisors Group LLC’s holdings in AstraZeneca were worth $383,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in AZN. Price T Rowe Associates Inc. MD lifted its stake in shares of AstraZeneca by 17.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 61,271,974 shares of the company’s stock valued at $4,151,177,000 after acquiring an additional 9,002,450 shares during the last quarter. Capital World Investors boosted its stake in shares of AstraZeneca by 0.3% during the first quarter. Capital World Investors now owns 9,365,676 shares of the company’s stock valued at $634,525,000 after purchasing an additional 29,497 shares in the last quarter. Envestnet Asset Management Inc. grew its holdings in shares of AstraZeneca by 16.7% during the second quarter. Envestnet Asset Management Inc. now owns 3,417,933 shares of the company’s stock worth $266,565,000 after purchasing an additional 488,644 shares during the last quarter. Clearbridge Investments LLC increased its stake in shares of AstraZeneca by 5.8% in the second quarter. Clearbridge Investments LLC now owns 3,403,748 shares of the company’s stock valued at $265,458,000 after buying an additional 186,010 shares during the period. Finally, Fayez Sarofim & Co raised its holdings in AstraZeneca by 4.7% in the 1st quarter. Fayez Sarofim & Co now owns 2,990,234 shares of the company’s stock valued at $202,588,000 after buying an additional 134,784 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Price Performance

Shares of NASDAQ AZN opened at $63.85 on Thursday. The company has a market capitalization of $197.97 billion, a PE ratio of 30.85, a P/E/G ratio of 1.32 and a beta of 0.47. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68. The firm has a fifty day simple moving average of $78.45 and a 200 day simple moving average of $78.75.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. TD Cowen upped their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.